DeCure for X-linked dyserythropoetic anemia with abnormal platelets and neutropenia
DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for X-linked dyserythropoetic anemia with abnormal platelets and neutropenia — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleX-linked dyserythropoetic anemia with abnormal platelets and neutropenia maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for x-linked dyserythropoetic anemia with abnormal platelets and neutropenia is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
A single case report from 1996 describes an 80-year-old woman who developed aplastic anaemia within five weeks of starting ticlopidine hydrochloride, a platelet aggregation inhibitor used for stroke prophylaxis. Neutropenia was already a known side effect of ticlopidine. That report has no connection to X-linked dyserythropoietic anaemia with abnormal platelets and neutropenia.
The disease itself is defined in a 2020 Orphanet entry as a rare, genetic, constitutional dyserythropoietic anaemia disorder. It features moderate to severe anaemia without thrombocytopenia, variable neutropenia, and bone marrow biopsy showing trilineage dysplasia with hypocellularity of erythroid and granulocytic lineages. Peripheral blood shows anisocytosis, macrocytosis, poikilocytosis, elliptocytes, and fragmented erythrocytes.
A 2006 study examined platelets from a pedigree with a GATA-1 G208S mutation, macrothrombocytopenia, and dyserythropoiesis without anaemia. Electron microscopy revealed wide variation in platelet size, shape, and internal structure. Most large cells were hypogranular. Some contained no membrane systems or organelles; others were filled with dense tubular system channels or tubular inclusions seen in Medich Giant Platelets Disorder. A unique finding was platelets within platelets, sometimes two inside one cell, and on rare occasions a platelet within a platelet within a platelet. This had never been observed in any human platelet disorder before. Another unique feature was frequent platelet-to-platelet surface attachment of non-activated cells, forming large macrothrombocytes unlike aggregates of stimulated normal platelets. The authors concluded that the macrothrombocytopenia, platelets within platelets, and surface attachments suggest a major defect in the formation and separation of platelets from pro-platelets of the parent megakaryocyte.
No clinical trial has tested any drug for this disease. No treatment data exist. What is missing is any funded effort to screen compounds, any patient-derived cell or animal model for drug testing, and any natural history study that could define endpoints for a future trial. Patient stratification by specific GATA-1 mutation has not been attempted in a treatment context.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Neurology · 1996 · 15 citations
Aplastic anemia associated with ticlopidine
AbstractTiclopidine hydrochloride (TH), a potent inhibitor of platelet aggregation, is widely used for stroke prophylaxis. [1] Neutropenia is a relatively common side effect, and appropriate precautions and recommendations for hematologic monitoring are recommended in the dispensing literature. [2] We report a case of aplastic anemia that developed within 5 weeks of initiation of TH therapy.
### Case report.
Our patient was an 80-year-old woman with a history of cerebrovascular …
X-linked dyserythropoietic anemia with abnormal platelets and neutropenia
AbstractOpe n Pe e r Re v ie w on Qe ios Ope n Pe e r Re v ie w on Qe ios X-linked dyserythropoietic anemia with abnormal platelets and neutropenia INSERM Source INSERM.(1999).Orphanet: an online rare disease and orphan drug data base.X-linked dyserythropoietic anemia with abnormal platelets and neutropenia.ORPHA:363727 X-linked dyserythropoietic anemia with abnormal platelets and neutropenia is a rare, genetic, constitutional dyserythropoietic anemia disorder characterized by moderate to severe anemia without thrombocytopenia, variable degrees of neutropenia, and bone marrow biopsy findings of trilineage dysplasia and hypocellularity of erythroid and granulocytic lineages.Peripheral blood findings include anisocytosis, macrocytosis, poikilocytosis, elliptocytes, and fragmented erythrocytes.
Platelet Pathology in GATA-1 Dyserythropoietic Macrothrombocytopenia.
AbstractAbstract Germline mutations in the X-linked hematopoietic transcription factor, GATA-1, have been associated with dyserythropoietic anemia (DEA), macrothrombocytopenia (MTP), and congenital erythropoietic porphyria. Recently, morphological features suggestive of the Gray Platelet Syndrome (GPS) were described in a pedigree with a germline R216Q GATA-1 mutation (Blood106:6a, 2005). The present study has evaluated platelets (Pl) in the electron microscope from members of a previously described pedigree (Blood98:2681–2688, 2001) with GATA-1 G208S, MTP, and dyserythropoiesis without anemia, for whom detailed platelet morphology studies have not been reported. The presence of a hemizygous GATA-1 mutation was confirmed by conventional fluorescent dye chemistry sequencing of DNA from patient peripheral blood mononuclear cells. Their Pl revealed wide variations in size, shape, internal and external structure. Some normal sized and giant Pl contained usual numbers of alpha granules and dense bodies, while most of the large cells were hypogranular. Some contained no membrane systems or organelles. Others were filled with masses of dense tubular system (DTS) channels, and others contained the tubular inclusions found in the Medich Giant Platelets Disorder (Platelets15:345–353, 2004). Many of the hypogranular cells contained small vacuoles that may have been enclosing membranes of alpha granules. Except for the tubular inclusions, all of these structural variations are observed in GPS Pl (Am. J. Pathol.95:445–462, 1979). However, additional striking abnormalities were seen in GATA-1 Pl that are not characteristic of GPS Pl. Many GATA-1 Pl contained unusual, closely associated dense double membranes differing from normal elements of rough endoplasmic reticulum, smooth endoplasmic reticulum, DTS or surface connected open canalicular system (OCS), but resembling channels of the OCS after exposure to EDTA. They were observed previously only in megakaryocytes (Mk) from one family with GATA-1 DEA-MTP (Nat. Genet, 24:266–270, 2000). The dense double membranes were often found in parallel association and, in some examples, isolating areas of cytoplasm. However, the isolated areas were not undergoing autophagic degradation as such areas enclosed by elements of the DTS do in White Platelet Syndrome Pl (Platelets 15:173,2004). Instead, they proved to be another unique feature of GATA-1 platelets, the presence of Pl within Pl. The sequestered cells were usually mature in appearance and often discoid in form with circumferential coils of microtubules. In some GATA-1 Pl there were two Pl within the same cell, and on rare occasions, a Pl within a Pl within a Pl. Pl within Pl have never been observed previously in any human platelet disorder. Another unique feature, related to Pl within Pl, was the frequent Pl to Pl surface attachment of non-activated cells forming large macrothrombocytes with no similarity to aggregates of stimulated normal platelets. Conclusion: The substructural abnormalities of Pl from patients with germline GATA-1 mutations share some overlap with those seen in GPS Pl, but are distinct and unique. The MTP, Pl within Pl and surface Pl to Pl attachments suggest a major defect in the formation and separation of GATA-1 Pl from pro-Pl of the parent Mk, resulting in the MTP characteristic of the disorder.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
